Ondexxya
(Remimazolam Besylate)Phase 3Small molecule
Remimazolam is used to put patients to sleep quickly during medical procedures and surgeries. It works fast and wears off quickly, making it useful for short procedures where doctors need patients unconscious for a brief time.[1] Ondexxya is currently being investigated across 10 indications[3], with its most advanced program in Phase 3.[1]
Ondexxya is one of 137 small molecule programs targeting Nausea and vomiting. It is currently in Phase 3.
10
Indications
34
Total Trials
10
Active Trials
136
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
137 competitors in Atrial Fibrillation
#DrugCompanyPhaseTrials
1Ondexxya
UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 3
Calquence
AstraZenecaPreclinical
Rituxan
RochePreclinical
Coumadin
AAbbott
Preclinical
Brukinsa
BBeOne Medicines
Preclinical
Imbruvica
PPharmacyclics LLC.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Romazicon
CConrado Roberto Hoffmann Filho
Preclinical
Statin
Bristol-Myers SquibbPreclinical
Low-Molecular-Weight Heparin
Daiichi SankyoPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sedation10 trials
Sedation Efficacy and Safety of Remazolam Besylate in Ventilated Surgical Critically Ill Patients
Recruiting·—·Phase 4·NCT06575530·306 enrolled
Show 7 more trials
The Effect of Wavelet Index in Monitoring the Sedation Depth of Remimazolam Besylate
Not yet recruiting·—··NCT06427785·30 enrolled
A Comparison of Remimazolam Besylate and Propofol Sedation in Patients Undergoing Colonoscopic Polypectomy
Recruiting·—·Phase 4·NCT07456111·90 enrolled
REMIMID-ICU: Remimazolam vs Midazolam for Deep Sedation in Hemodynamically Unstable, Mechanically Ventilated Adults
Not yet recruiting·—·Phase 3·NCT07155265·180 enrolled
Long-term Sedation With Remimazolam Besylate in Critically Ill Patients
Unknown status·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 3·NCT05555667·728 enrolled
Remimazolam7 trials
Remimazolam Besylate3 trials
The ED95 of Single Intravenous Bolus Remimazolam Besylate in Pediatric Patients During General Anesthesia Induction
Completed·SSecond Affiliated Hospital of Wenzhou Medical University·Phase 4·NCT06061159·120 enrolled
The Efficacy and Safety of Remimazolam Besylate for Cardiac Anesthesia
Not yet recruiting·—·Phase 1·NCT06717945·320 enrolled
Treatment1 trial
12 more indications
Nausea and vomiting1 trial
Total Intravenous Anesthesia1 trial
Hemodynamic Stability1 trial
Atrial Fibrillation1 trial
Elderly Patients1 trial
Postoperative Quality of Recovery1 trial
Postoperative Quality of Recovery After General Anesthesia With Remimazolam
Unknown status·—·N/A·NCT06332157·126 enrolled
Aortic Aneurysm1 trial
Aortic Aneurysm, Thoracoabdominal1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Remimazolam Besylate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details